Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 9/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.36 |
| ▸ | MGMT | P16455 | 2/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL22775220 | 0.73 | PDPK1 (0.60) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.72 | PDPK1 (0.92) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.72 | PDPK1 (1.00) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28189513 | 0.72 | ADRB1 (0.41) | PDPK1GDAMGMTPNP | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.71 | PDPK1 (0.96) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.71 | PDPK1 (0.96) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.71 | PDPK1 (0.96) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28083713 | 0.70 | PDPK1 (0.79) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL9220451 | 0.68 | PDPK1 (0.64) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL4535059 | 0.67 | PDPK1 (0.79) | PDPK1GDADPP4CDK2MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | SPRING BREAK PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3524252-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10376533-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2956145-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150329864-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138442-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9040234-B2 | Oligonucleotide analogs as therapeutic agents | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014127378-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| US-20130197066-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2611451-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8404651-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012030626-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2271351-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009146123-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376533-B2 | Compositions and methods for treating viral infections | SLC10A1, HAVCR2, CYP3A43 | PDPK1 4293/4885GDA 681/4885DPP4 754/4885 |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | PDPK1 4293/4885GDA 681/4885DPP4 754/4885 |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | PDPK1 4293/4885GDA 681/4885DPP4 754/4885 |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | PDPK1 4033/4885GDA 187/4885DPP4 770/4885 |
| US-20130197066-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | PDPK1 4293/4885GDA 681/4885DPP4 754/4885 |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | TLR3, TLR5, TLR9 | PDPK1 3882/4885GDA 207/4885DPP4 865/4885 |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | PDPK1 2353/4885GDA 689/4885DPP4 559/4885 |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | PDPK1 4293/4885GDA 681/4885DPP4 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.